
Trump's lonely attacks on Powell
Presented by
Editor's note: Morning Money is a free version of POLITICO Pro Financial Services morning newsletter, which is delivered to our subscribers each morning at 5:15 a.m. The POLITICO Pro platform combines the news you need with tools you can use to take action on the day's biggest stories. Act on the news with POLITICO Pro.
Quick Fix
President Donald Trump called on lawmakers to work over Federal Reserve Chair Jerome Powell for keeping interest rates elevated. In the first of two scheduled hearings on central bank policy this week, GOP Congress members left their pipes and brass knuckles at home.
House Financial Services Republicans on Tuesday offered little pushback to the Fed chair's case for keeping borrowing costs steady until there's greater clarity on how the president's tariff policies ultimately affect consumer prices. Reps. Mike Lawler of New York and Bill Huizenga of Michigan offered up resistance — with Lawler channeling Trump in saying Powell is already too late when it comes to easing financial conditions — but no one went the full monty in echoing the president's name-calling or public harangues.
The Hill's tepid resistance to Powell on rates suggests there are still limits to how far most congressional Republicans will go when it comes to the Fed. Since returning to the White House, Trump has demonstrated an extraordinary ability to dictate the GOP's messaging and policy agenda. Yet few lawmakers are willing to match the president's theatrics when it comes to Powell, who has spent years building relationships with key members of both parties.
'There is relatively little policy reason to join that attack on Powell,' said Sarah Binder, a professor at George Washington University and a senior fellow in Governance Studies at the Brookings Institution. Inflation has fallen, and the labor market still seems to be humming along at a healthy pace, she added. 'It makes sense that Republicans might be a little hesitant to pour more fuel on the fire.' Powell is scheduled to testify before Senate Banking at 10 a.m. today.
Many GOP leaders — and Democrats, for that matter — would like to see the Fed bring down financing costs, particularly given the housing market's struggles. The combined effects of tariff uncertainty and tight financing conditions have created a challenging environment for central bank policymakers who hold increasingly divergent views on the rate path. Consumer confidence in the economic outlook is sputtering, according to a Conference Board survey released Tuesday, but so far the gloom hasn't been reflected in employment or inflation data. (Powell testified that the Fed could pivot to reducing rates if the tariff-related inflation many economists expect to arrive this summer is muted, or if the labor market softens).
The view within the White House is that the Fed chair's speculation about how tariff policies could affect inflation has held up Trump's ability to spur domestic manufacturing and private investment, both of which are fundamental to Trump's long-term economic goals. Federal Housing Finance Agency Director William Pulte — who last week called for Powell's resignation — posted Tuesday that the Fed chair's policies are hurting 'real people who work good & hard, and are just trying to pay their car loans, credit cards, & mortgages.'
Even so, there's also a recognition among Republicans that insulating Powell from political influence has its merits. Rep. Frank Lucas (R-Okla.) — the longest-serving Financial Services Republican — has been pushing for bipartisan legislation to do just that. And given how quickly economic outlooks have shifted during the Trump 2.0 era, it may be against the interests of GOP lawmakers to undermine public trust in a central banker who navigated the worst period of inflation in 40 years without triggering a recession.
'You don't want to weaken him. You want to strengthen him,' said Josh Lipsky, a former State Department and IMF official who's now the senior director of the Atlantic Council's GeoEconomics Center. 'More likely than not, we're going to have another bout of volatility in the coming months.'
IT'S WEDNESDAY — Send MM tips and pitches to me at ssutton@politico.com.
Driving the Day
The Bitcoin Policy Institute holds its 2025 policy summit with speakers including White House crypto adviser Bo Hines, Sen. Cynthia Lummis, House Majority Whip Tom Emmer, Rep. Warren Davidson and SEC Commissioner Hester Peirce. … Powell testifies before Senate Banking at 10 a.m. … House Financial Services holds a hearing on 'Reassessing Sarbanes-Oxley' at 10 a.m. … New home sales data is out at 10 a.m. … The Fed meets to discuss proposed revisions to its supplementary leverage ratio standards at 2 p.m. …
Previewing Powell — Katherine Hapgood reports that Senate Banking Republicans led by Sen. Tim Scott (R-S.C.) will ask Powell to 'address the Fed's 'lavish renovations, the agency's politicization and the need to empower newly confirmed Vice Chair for Supervision, Governor Michelle Bowman.''
Coalition time for 'O-Triple B' — Later this morning, Treasury Secretary Scott Bessent, Deputy Secretary Michael Faulkender and National Association of Manufacturers President and CEO Jay Timmons — along with representatives from U.S. manufacturing companies across the country — will convene at 9 a.m. to discuss Trump's megabill as the Senate moves to finalize its version, according to two people granted anonymity to discuss internal plans. Bessent met with Senate Republicans on Tuesday to encourage lawmakers to meet the president's July 4 deadline. NAM has been pushing for the bill's passage.
— Bessent met with Senate GOP members to encourage Congress to get the legislation to the president's desk by July 4, Jordain Carney reports. Per Meredith Lee Hill, House Speaker Mike Johnson has instructed lawmakers not to leave town and to keep their schedules flexible.
— The July 4 deadline is tight given how many policy questions are still outstanding, report Richard Rubin and Siobhan Hughes for WSJ. Deficit hawks in the House are starting to squawk over the Senate's version, which the Joint Committee on Taxation estimates will cost $4.2 trillion.
— Bessent told reporters that he expects Republicans will reach an agreement on the state and local tax deduction cap 'in the next 24-48 hours,' according to Bloomberg's Cam Kettles and Nacha Cattan.
Well, well, well — The Trump administration's attacks on Big Pharma have hammered the industry's share prices. In Washington, lawmakers are buying the dip, Amanda Chu reports.
— 'Representatives and senators purchased up to $2.9 million in pharmaceutical stocks in the first six months of the Trump administration, financial disclosures say, and Republicans outpaced Democrats in share purchases, investing as much as $1.8 million in drug companies, while Democrats were more likely to sell assets.'
The Economy
Soft data, muddy waters — The Chamber of Commerce's quarterly Small Business Index reflected a slight uptick in the economic outlook, according to survey data shared with MM. Slightly more than a third of the businesses surveyed said the economy is in good health, an increase from 29 percent during the first quarter. Fewer than 50 percent selected inflation as their chief concern — a first since mid-2022.
— JPMorgan's 2025 Business Leaders Outlook Pulse Survey — also out this morning — found that leaders of mid-sized businesses with between $20 million and $500 million of annual revenue are increasingly pessimistic in their economic outlook. Just 32 percent say they're optimistic, a decline of more than half since the start of the year, and roughly a quarter of respondents now expect a recession. Nearly 75 percent of those surveyed cited policy uncertainty as a reason for delaying their business plans this year.
'Businesses are operating with caution in the current environment,' Matt Sable, the co-head of JPMorgan Commercial Banking, said in a statement. 'Leaders are recalibrating where necessary to ensure they can continue to deliver for their clients and communities, highlighting their resilience and determination.'
Crypto
Floor vote — House leaders are looking at holding a vote on crypto legislation as soon as the week of July 7, Jasper Goodman reports. It may include a legislative package that would include new rules for dollar-pegged stablecoins as well as a broader crypto market structure bill, but no final decision has been made on whether or how to marry the efforts.
Uh-oh — The Bank for International Settlements — an organization known as the central bank of central banks — is cautioning about the proliferation of stablecoins, Declan Harty reports. The tokens do show 'some attributes of money,' the BIS said in a chapter in its annual economic report. But stablecoins 'fall short' of qualifying as a type of sound money — in part because of their potential use for money laundering and terrorism financing, it said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Los Angeles Times
28 minutes ago
- Los Angeles Times
Court orders Trump administration to facilitate another deported man's return from El Salvador
WASHINGTON — A federal appeals court in New York on Tuesday ordered the Trump administration to facilitate the return of a man who was deported to El Salvador roughly 30 minutes after the court suspended an order to remove him from the U.S. The ruling in Jordin Alexander Melgar-Salmeron's case marks at least the fourth time this year that President Trump's administration has been ordered to facilitate the return of somebody mistakenly deported. The government said 'a confluence of administrative errors' led to Melgar-Salmeron's deportation on May 8, according to the decision by a three-judge panel from the 2nd U.S. Circuit Court of Appeals. The panel said administration officials must facilitate his return to the U.S. 'as soon as possible.' The judges gave them a week to identify his current physical location and custodial status and to specify what steps they will take to facilitate his return. Kilmar Abrego Garcia, whose mistaken deportation in March became a flashpoint in Trump's immigration crackdown, was returned from El Salvador this month to face human smuggling charges in Tennessee. In April, a Trump-nominated judge in Maryland ordered his administration to facilitate the return of a man who was deported to El Salvador in March despite having a pending asylum application. U.S. District Judge Stephanie Gallagher ruled that the government violated a 2019 settlement agreement when it deported the 20-year-old man, a Venezuelan native identified only as Cristian in court papers. And in May, another judge ordered the administration to facilitate the return of a Guatemalan man whom it deported to Mexico despite his fears of being harmed there. U.S. District Judge Brian Murphy found that the removal of the man, who is gay, likely 'lacked any semblance of due process.' Kunzelman writes for the Associated Press.
Yahoo
28 minutes ago
- Yahoo
The Goldman Sachs Group, Inc. (GS) Is Experiencing A Lot Of Momentum, Believes Jim Cramer
The Goldman Sachs Group, Inc. (NYSE:GS) is one of the . The Goldman Sachs Group, Inc. (NYSE:GS) is one of the largest investment banks in the world. The shares have gained 11.5% year-to-date as investors look to increased capital markets activity. The investment banking industry has been suffocated for quite some time as high rates and sluggish economic activity have raised the stakes for firms to go public or conduct mergers and acquisitions. 2025 has seen a couple of IPOs hit the market, and The Goldman Sachs Group, Inc. (NYSE:GS)'s shares are reflective of the easing market. Cramer commented on these trends: 'I think that it's project momentum over at Goldman. I think that they're doing incredibly well. I know David had been tepid about the deal flow and that you also said that IPOs really don't matter.' In his earlier remarks about The Goldman Sachs Group, Inc. (NYSE:GS), Cramer discussed the IPO market and the government's policies: 'If you take a step back for a second and consider the theme in the aggregate, it's a very easy time to play an uptick in IPOs, just buy the investment bank that's the best under the sun and that's Goldman Sachs. Now, of the big banks, they're the most levered to investment banking, and that includes IPOs and underwriters. We've owned Goldman Sachs for the Charitable Trust since late last year, primarily because I thought we'd see an uptick in deal activity this year as the Trump administration replaced the Biden administration. A close-up of a financial advisor giving advice to a customer, demonstrating the importance of consumer and wealth management. But as it became clear that the new Trump administration was going to prioritize tariffs over its more pro business policies, that's a real negative for both IPOs and M&A, this thing pulled back hard, only falling nearly 35% from peak to trough by the time it bottomed at $440 [on] April 7th. Since then, though, Goldman's been rallying hard in part because of the IPO market bouncing back and also because there's been a pickup in mergers and acquisitions…. While we acknowledge the potential of GS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
China is a real threat to US biotech innovation: EY life science expert
China's growing biotech prowess has become a real threat to the industry in the US in recent years. Moves by the Trump administration could weaken the US market further, according to several experts watching the deals flowing into China, which amounted $30 billion in 2024 and are already more than half that total in mid-2025. EY life sciences leader Arda Ural is among those watching and said that China is no longer the land of generics and active pharmaceutical ingredients (APIs) used by the rest of the world. China has long been known as a "me too" producer — that is, a manufacturer of generics — as well as a source of APIs. But China is showing its might as it clinches more licensing deals for drugs developed domestically and increases clinical trials being conducted in the country. "The numbers are pretty compelling," Ural told Yahoo Finance. "A couple of years ago, we had pretty much no deals, or maybe under $1 billion in 2016. As of last year, there were $30 billion of licensing deals of Chinese assets into the US." But this didn't happen overnight. The Chinese Communist Party laid out a roadmap in 2015 that included investing in and growing the country's biotech sector. Ten years later, that is coming to fruition, Ural said. "That journey now is taking them upstream to more advanced innovation. Probably, we still have not seen first-in-class, but clearly they are going for best-in-class," Ural said. US companies buying or licensing products from China include a due diligence process, which can involve head-to-head comparisons to existing drugs or repeating clinical trials to ensure the data and efficacy results are accurate. This has helped ease concerns about intellectual property theft of US products, as well as concerns about data integrity in China. The prior doubts spurred the introduction of the Biosecure Act in Congress in 2023, which would prevent any entity receiving federal funds from using biotech equipment or services from "companies of concern." That bill has stalled in Congress. Meanwhile, the life sciences community continues to increase its interest in China. Companies like WuXi Biologics (WXXWY), WuXi AppTec (WUXAY), and BGI (formerly Beijing Genomics Institute) are among those under the spotlight. And during the pandemic, companies like CanSino ( which developed a vaccine, came into view. Now, with cuts to research funding in the US to the National Institutes of Health (NIH), as well as the loss of Food and Drug Administration staff, insiders are warning that China could fill the gaps and scoop up talent from the US. "The US still has the capacity to invest, but it is not, potentially, the only game in town," Ural said. He explained that China is still early in its journey, and while it does have government funding and Western-educated doctors and researchers, it doesn't have the type of firepower of US capital markets. "That is where they are lacking. There is no IPO market comparable to Western markets, there is no M&A exit strategy ... so that's the opportunity for them to come up," Ural said. A majority of the deals so far are US-based companies buying early-stage assets from Chinese company pipelines, bringing them to the US to validate and then produce and sell. At the same time, the US-based biotech industry has seen a slowdown in investment and IPO activity, and the NIH funding cuts by the Trump administration are exacerbating the dry spell. China's growth is also adding to the pressure since China is known for making things cheaper and faster than Western countries. Ural said that's why the partnership with US-based firms is a "winning strategy" for the overall industry. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices